Literature DB >> 18249000

Non-small cell lung cancer with ipsilateral pulmonary metastases: prognosis analysis and staging assessment.

Jin Gu Lee1, Chang Young Lee, Dae Joon Kim, Kyung Young Chung, In Kyu Park.   

Abstract

OBJECTIVE: Although designated as T4 or M1 in the current TNM classification system revised in 1997, non-small cell lung cancer with ipsilateral pulmonary metastases is treated as a locally advanced disease and reported survival rates are relatively good. We intended to analyze the prognosis of ipsilateral pulmonary metastases and validate current TNM classification system.
METHODS: Data of 1213 surgically treated patients with non-small cell lung cancer from January 1990 to December 2004 were retrospectively reviewed. Overall and disease-free survival rates of patients with ipsilateral pulmonary metastases and other T stages were obtained by the Kaplan-Meier method and compared by the log rank test. Prognostic impact of ipsilateral pulmonary metastases on disease-free survival was sought by multivariate analysis.
RESULTS: Among 49 patients with ipsilateral pulmonary metastases (IPM), 23 patients had metastasis in primary lobe (IPM1) and 26 had metastasis in non-primary lobe (IPM2). Five-year overall and disease-free survival rates of IPM1 and IPM2 were not significantly different (30.3% vs 30.7%, p=0.95, 21.9% vs 23.1%, p=0.78). Prognoses of IPM1 and IPM2 were not significantly different than those of T3 disease (30.1%, 26.6%). Resected T4 disease excluding IPM1 had a tendency to show the worse prognosis (16.2%, 7.5%) without significant difference with IPM1 and IPM2. In the univariate analysis of prognostic factors for disease-free survival, IPM1 and IPM2 were prognostic factors. In the multivariate analysis, IPM2 (1.554, 1.02-2.34, p=0.039) was one of independent negative prognostic factors. However, IPM1 was not an independent prognostic factor (1.31, 0.84-2.04, p=0.23).
CONCLUSIONS: Regarding prognosis, prognostic strength, extent of disease and surgical treatment the current TNM classification system may be inappropriate in designation of ipsilateral pulmonary metastases and needs revision. The authors suggest that the IPM1 should be staged as T3 or designated as upstaging co-parameter of T stage as like in 1992 TNM classification and IPM2 can be staged as T4 as like in 1992 TNM classification.

Entities:  

Mesh:

Year:  2008        PMID: 18249000     DOI: 10.1016/j.ejcts.2007.12.005

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  3 in total

1.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Authors:  Ramón Rami-Porta; Hisao Asamura; Peter Goldstraw
Journal:  Transl Lung Cancer Res       Date:  2015-08

2.  TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling.

Authors:  Lingyi Fu; Ke Shi; Jingshu Wang; Wangbing Chen; Dingbo Shi; Yun Tian; Wei Guo; Wendan Yu; Xiangsheng Xiao; Tiebang Kang; Shusen Wang; Wenlin Huang; Wuguo Deng
Journal:  Mol Cancer       Date:  2014-04-26       Impact factor: 27.401

3.  MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm.

Authors:  Wei Wang; Zaoxiu Hu; Mingsheng Ma; Haoyuan Yin; Yunchao Huang; Guangqiang Zhao; Xin Cui; Qinling Sun; Yantao Yang; Yichen Yang; Biying Wang; Lianhua Ye
Journal:  Ther Clin Risk Manag       Date:  2021-12-03       Impact factor: 2.755

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.